DE69435330D1 - Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen - Google Patents

Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen

Info

Publication number: DE69435330D1
Authority: DE; Germany
Prior art keywords: medicament; manufacture; treatment; botulinum toxin; toxin type
Prior art date: 1993-12-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69435330T

Other languages

English (en)

Inventor

Roger K Aoki

Michael W Grayston

Steven R Carlson

Judith M Leon

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Allergan Inc

Original Assignee

Allergan Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-12-28

Filing date

1994-12-16

Publication date

2011-01-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22634387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69435330(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-12-16 Application filed by Allergan Inc filed Critical Allergan Inc

2011-01-27 Application granted granted Critical

2011-01-27 Publication of DE69435330D1 publication Critical patent/DE69435330D1/de

2014-12-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE69435330T 1993-12-28 1994-12-16 Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen Expired - Lifetime DE69435330D1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17399693A	1993-12-28	1993-12-28

Publications (1)

Publication Number	Publication Date
DE69435330D1 true DE69435330D1 (de)	2011-01-27

Family

ID=22634387

Family Applications (23)

Application Number	Title	Priority Date	Filing Date
DE69428813T Expired - Lifetime DE69428813T2 (de)	1993-12-28	1994-12-16	Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
DE69435194T Expired - Lifetime DE69435194D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434319T Expired - Lifetime DE69434319T3 (de)	1993-12-28	1994-12-16	Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen
DE69427869T Expired - Lifetime DE69427869T2 (de)	1993-12-28	1994-12-16	Botulinumtoxine zur behandlung von hyperhydrosis
DE69434535T Revoked DE69434535T2 (de)	1993-12-28	1994-12-16	Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE69435116T Expired - Lifetime DE69435116D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE122009000038C Pending DE122009000038I1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69435302T Expired - Lifetime DE69435302D1 (de)	1993-12-28	1994-12-16	Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE69435270T Expired - Lifetime DE69435270D1 (de)	1993-12-28	1994-12-16	Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69434511T Expired - Lifetime DE69434511T2 (de)	1993-12-28	1994-12-16	Botulinumtoxin zur Behandlung von Dystonie
DE69434610T Expired - Lifetime DE69434610T2 (de)	1993-12-28	1994-12-16	Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE122008000042C Pending DE122008000042I1 (de)	1993-12-28	1994-12-16	Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69435243T Expired - Lifetime DE69435243D1 (de)	1993-12-28	1994-12-16	Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69434540T Expired - Lifetime DE69434540T2 (de)	1993-12-28	1994-12-16	Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE122008000043C Pending DE122008000043I1 (de)	1993-12-28	1994-12-16	Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE69435330T Expired - Lifetime DE69435330D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69434443T Revoked DE69434443T2 (de)	1993-12-28	1994-12-16	Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
DE69435249T Expired - Lifetime DE69435249D1 (de)	1993-12-28	1994-12-16	Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69435321T Expired - Lifetime DE69435321D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69433394T Expired - Lifetime DE69433394T3 (de)	1993-12-28	1994-12-16	Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
DE69434008T Expired - Lifetime DE69434008T2 (de)	1993-12-28	1994-12-16	Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
DE69435149T Expired - Lifetime DE69435149D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
DE69435276T Expired - Lifetime DE69435276D1 (de)	1993-12-28	1994-12-16	Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie

Family Applications Before (15)

Application Number	Title	Priority Date	Filing Date
DE69428813T Expired - Lifetime DE69428813T2 (de)	1993-12-28	1994-12-16	Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
DE69435194T Expired - Lifetime DE69435194D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69434319T Expired - Lifetime DE69434319T3 (de)	1993-12-28	1994-12-16	Botulinustoxine A oder B zur Behandlung von Schmerzen verbunden mit Glattmuskelkrämpfen
DE69427869T Expired - Lifetime DE69427869T2 (de)	1993-12-28	1994-12-16	Botulinumtoxine zur behandlung von hyperhydrosis
DE69434535T Revoked DE69434535T2 (de)	1993-12-28	1994-12-16	Toxische Komponente der Botulinumtoxine zur Modulation cholinergisch kontrollierter Sekretionen
DE69435116T Expired - Lifetime DE69435116D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin für die Herstellung eines Arzneimittels zur Linderung von Rückenschmerzen
DE122009000038C Pending DE122009000038I1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Reduzierung von Schmerzen bedingt durch Muskelkrankheit
DE69435302T Expired - Lifetime DE69435302D1 (de)	1993-12-28	1994-12-16	Neurotoxisches Komponent eines Botulinumtoxins zur Behandlung von Spätdyskinesie
DE69435270T Expired - Lifetime DE69435270D1 (de)	1993-12-28	1994-12-16	Verwendung der neurotoxischen Komponente von Botulinum Toxin zur Behandlung spastischer Muskeln
DE69434511T Expired - Lifetime DE69434511T2 (de)	1993-12-28	1994-12-16	Botulinumtoxin zur Behandlung von Dystonie
DE69434610T Expired - Lifetime DE69434610T2 (de)	1993-12-28	1994-12-16	Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE122008000042C Pending DE122008000042I1 (de)	1993-12-28	1994-12-16	Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
DE69435243T Expired - Lifetime DE69435243D1 (de)	1993-12-28	1994-12-16	Verwendung vom neurotoxischem Komponent von Botulinum Toxin zur Behandlung von Glattmuskelkrankheiten
DE69434540T Expired - Lifetime DE69434540T2 (de)	1993-12-28	1994-12-16	Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie
DE122008000043C Pending DE122008000043I1 (de)	1993-12-28	1994-12-16	Neurotoxisches Komponente von Botulinumtoxinen zur Behandlung von zervikaler Dystonie

Family Applications After (7)

Application Number	Title	Priority Date	Filing Date
DE69434443T Revoked DE69434443T2 (de)	1993-12-28	1994-12-16	Verwendung der neutrotoxischen Komponente des Botulinum Toxins zur Muskelschmerzbehandlung
DE69435249T Expired - Lifetime DE69435249D1 (de)	1993-12-28	1994-12-16	Verwendung vom neurotoxischem Komponent von Botulinum toxin zur Behandlung von einem spastischem Muskel
DE69435321T Expired - Lifetime DE69435321D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinum Toxin zur Behandlung des myofascialen Schmerzsyndroms
DE69433394T Expired - Lifetime DE69433394T3 (de)	1993-12-28	1994-12-16	Botulinustoxine zur Modulation cholinergisch-kontrollierter Sekretionen
DE69434008T Expired - Lifetime DE69434008T2 (de)	1993-12-28	1994-12-16	Botulinumtoxin zur Behandlung von mit Muskelkrankheiten verbundenen Schmerzen
DE69435149T Expired - Lifetime DE69435149D1 (de)	1993-12-28	1994-12-16	Verwendung von Botulinum Toxine gegen Schwitzen bei Menschen
DE69435276T Expired - Lifetime DE69435276D1 (de)	1993-12-28	1994-12-16	Verwendung vom neurotoxischen Komponent der Botulinum Toxin zur Muskelschmerzbehandlung bei cervikaler Dystonie

Country Status (9)

Country	Link
EP (23)	EP1563843B1 (de)
JP (33)	JP3238154B2 (de)
AU (1)	AU688452B2 (de)
CA (2)	CA2682117A1 (de)
DE (23)	DE69428813T2 (de)
ES (18)	ES2163090T3 (de)
FR (1)	FR08C0034I1 (de)
HK (6)	HK1033274A1 (de)
WO (1)	WO1995017904A2 (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9120306D0 (en)	1991-09-24	1991-11-06	Graham Herbert K	Method and compositions for the treatment of cerebral palsy
DE122009000066I2 (de)	1993-06-10	2010-12-30	Allergan Inc	Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
US8557256B2 (en)	1993-12-28	2013-10-15	Allergan, Inc.	Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en)	1993-12-28	2012-05-29	Allergan, Inc.	Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
ES2163090T3 (es) *	1993-12-28	2002-01-16	Allergan Sales Inc	Uso de toxina botulinica para tratar la cefalea tensional.
US6974578B1 (en) *	1993-12-28	2005-12-13	Allergan, Inc.	Method for treating secretions and glands using botulinum toxin
AU2007202480B2 (en) *	1993-12-28	2009-01-29	Allergan, Inc.	Method for treating pain associated with a muscle disorder
ATE292977T1 (de) *	1994-05-09	2005-04-15	William J Binder	Präsynaptische neurotoxine gegen migränekopfschmerzen
US5721215A (en) *	1996-03-20	1998-02-24	Allergan	Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en)	1996-07-08	2004-03-02	University Of Massachusetts	Proteins within the type E botulinum neurotoxin complex
US6780413B2 (en)	1996-09-19	2004-08-24	The United States Of America As Represented By The Department Of Health And Human Services	Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders
AU2006225229B2 (en) *	1997-07-15	2006-12-07	Allergan, Inc.	Use of neurotoxin therapy for treatment of urologic and related disorders
US7470431B2 (en)	1997-07-15	2008-12-30	The Regents Of The University Of Colorado	Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
DE69833059T3 (de)	1997-07-15	2014-12-18	The Regents Of The University Of Colorado, A Body Corporate	Verwendung von Botulinumtoxin zur Behandlung von Harninkontinenz
US7455845B2 (en)	1997-07-15	2008-11-25	The Regents Of The University Of Colorado	Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
US9066943B2 (en)	1997-07-15	2015-06-30	The Regents Of The University Of Colorado	Use of botulinum toxin therapy for treatment of urological neurological conditions
AU2008201535C1 (en) *	1997-07-15	2013-09-12	Allergan, Inc.	Use of neurotoxin therapy for treatment of urologic and related disorders
US7449192B2 (en)	1997-07-15	2008-11-11	The Regents Of The University Of Colorado	Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US6063768A (en) *	1997-09-04	2000-05-16	First; Eric R.	Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en)	1997-10-08	1997-12-03	Speywood Lab The Limited	Analgesic conjugates
CA2319113A1 (en)	1998-01-26	1999-07-29	University Of Massachusetts	Biologically active hemagglutinin from type a clostridium botulinum and methods of use
US20040071736A1 (en)	1998-08-25	2004-04-15	Health Protection Agency	Methods and compounds for the treatment of mucus hypersecretion
US8790897B2 (en)	1998-08-25	2014-07-29	Syntaxin Ltd.	Treatment of mucus hypersecretion
GB9818548D0 (en)	1998-08-25	1998-10-21	Microbiological Res Authority	Treatment of mucas hypersecretion
TW574036B (en)	1998-09-11	2004-02-01	Elan Pharm Inc	Stable liquid compositions of botulinum toxin
DE19856897A1 (de) *	1998-12-10	2000-06-15	Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh	Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de)	1999-06-07	2000-12-21	Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh	Therapeutikum mit einem Botulinum-Neurotoxin
US6977080B1 (en) *	1999-08-10	2005-12-20	Allergan, Inc.	Intrapericardial botulinum toxin treatment for bradycardia
US6767544B2 (en) *	2002-04-01	2004-07-27	Allergan, Inc.	Methods for treating cardiovascular diseases with botulinum toxin
GB9922554D0 (en)	1999-09-23	1999-11-24	Microbiological Res Authority	Inhibition of secretion from non-neuronal cells
US7838008B2 (en)	1999-12-07	2010-11-23	Allergan, Inc.	Methods for treating diverse cancers
US6139845A (en)	1999-12-07	2000-10-31	Allergan Sales, Inc.	Method for treating cancer with a neurotoxin
US6261572B1 (en)	2000-01-11	2001-07-17	Allergan Sales, Inc.	Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en)	2000-01-11	2002-01-08	Allergan Sales, Inc.	Methods for treating diabetes
US6143306A (en) *	2000-01-11	2000-11-07	Allergan Sales, Inc.	Methods for treating pancreatic disorders
US6358513B1 (en) *	2000-02-15	2002-03-19	Allergan Sales, Inc.	Method for treating Hashimoto's thyroiditis
US6524580B1 (en) *	2000-02-15	2003-02-25	Allergan Sales, Inc.	Method for treating thyroid disorders
US6328977B1 (en) *	2000-02-22	2001-12-11	Allergan Sales, Inc.	Method for treating hyperparathyroidism
US6464986B1 (en)	2000-04-14	2002-10-15	Allegan Sales, Inc.	Method for treating pain by peripheral administration of a neurotoxin
US6565870B1 (en)	2000-04-28	2003-05-20	Allergan, Inc.	Methods for treating bone tumors
US6306403B1 (en) *	2000-06-14	2001-10-23	Allergan Sales, Inc.	Method for treating parkinson's disease with a botulinum toxin
AU2001276005A1 (en) *	2000-08-02	2002-02-13	Allergan Sales, Inc.	Method for treating a neoplasm
US6423319B1 (en) *	2000-10-04	2002-07-23	Allergan Sales, Inc.	Methods for treating muscle injuries
US6827931B1 (en)	2000-10-20	2004-12-07	Allergan, Inc.	Method for treating endocrine disorders
US20020086036A1 (en)	2000-12-05	2002-07-04	Allergan Sales, Inc.	Methods for treating hyperhidrosis
US7255865B2 (en)	2000-12-05	2007-08-14	Allergan, Inc.	Methods of administering botulinum toxin
ITUD20010002A1 (it)	2001-01-05	2002-07-05	Univ Degli Studi Udine	Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
GB0111146D0 (en) *	2001-05-04	2001-06-27	Imp College Innovations Ltd	Methods
JP2003009897A (ja)	2001-07-03	2003-01-14	Keiji Oguma	ボツリヌス毒素の分離・精製法
KR20030018827A (ko) *	2001-08-31	2003-03-06	서구일	Ａ형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제
US7255866B2 (en)	2001-09-17	2007-08-14	Allergan, Inc.	Botulinum toxin therapy for fibromyalgia
US6623742B2 (en)	2001-09-17	2003-09-23	Allergan, Inc.	Methods for treating fibromyalgia
US20030113349A1 (en)	2001-12-18	2003-06-19	Coleman William P.	Topically applied clostridium botulinum toxin compositions and treatment methods
US6921538B2 (en) *	2002-05-10	2005-07-26	Allergan, Inc.	Therapeutic treatments for neuropsychiatric disorders
US6776991B2 (en)	2002-06-26	2004-08-17	Allergan, Inc.	Methods for treating priapism
US20040009180A1 (en)	2002-07-11	2004-01-15	Allergan, Inc.	Transdermal botulinum toxin compositions
CA2501856A1 (en) *	2002-10-15	2004-04-29	Allergan, Inc.	Botulinum toxin dental therapies and procedures
US20040086532A1 (en)	2002-11-05	2004-05-06	Allergan, Inc.,	Botulinum toxin formulations for oral administration
US7238357B2 (en)	2002-11-05	2007-07-03	Allergan, Inc.	Methods for treating ulcers and gastroesophageal reflux disease
WO2004078201A1 (en) *	2003-03-06	2004-09-16	Botulinum Toxin Research Associates, Inc.	Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US7335367B2 (en)	2003-03-06	2008-02-26	Botulinum Toxin Research Associates, Inc.	Treatment of chronic chalazion and hordeolum with botulinum toxin
US7220422B2 (en)	2003-05-20	2007-05-22	Allergan, Inc.	Methods and compositions for treating eye disorders
FR2857595B1 (fr) *	2003-07-18	2005-10-07	Sod Conseils Rech Applic	Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie
US8609112B2 (en)	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
US8617572B2 (en)	2003-10-29	2013-12-31	Allergan, Inc.	Botulinum toxin treatments of depression
US8734810B2 (en)	2003-10-29	2014-05-27	Allergan, Inc.	Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8609113B2 (en)	2003-10-29	2013-12-17	Allergan, Inc.	Botulinum toxin treatments of depression
US7276244B2 (en)	2004-02-12	2007-10-02	Philip Radovic	Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
CA2555939A1 (en) *	2004-02-12	2005-09-01	Philip Radovic	Treatment of abnormalities of the first metatarsophalangeal joint of the foot
US20050191321A1 (en) *	2004-02-26	2005-09-01	Allergan, Inc.	Methods for treating headache
SI2656859T1 (sl)	2004-03-03	2016-02-29	Revance Therapeutics, Inc.	Topična aplikacija in transdermalna dostava botulinskih toksinov
US9211248B2 (en)	2004-03-03	2015-12-15	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP2007527431A (ja)	2004-03-03	2007-09-27	ルバンスセラピュティックス	局所的診断及び治療用の輸送のための組成物及び方法
AU2006218431B2 (en)	2005-03-03	2012-12-06	Revance Therapeutics, Inc.	Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1747782A1 (de)	2005-07-19	2007-01-31	Cesare Montecucco	Produkte zur topischen Anwendung enthaltend Lysophospholipide und Fettsäuren
US7910116B2 (en)	2005-08-24	2011-03-22	Allergan, Inc.	Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
CA2629499A1 (en)	2005-11-17	2007-05-24	Revance Therapeutics, Inc.	Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
WO2007095486A1 (en) *	2006-02-13	2007-08-23	Allergan, Inc.	Methods of treating blepharospasm using cyclosporine components
US7794386B2 (en)	2006-03-15	2010-09-14	Allergan, Inc.	Methods for facilitating weight loss
US7811586B2 (en)	2006-05-02	2010-10-12	Allergan, Inc.	Methods for alleviating testicular pain
FR2902341B1 (fr)	2006-06-16	2011-02-25	Scras	Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
AR061669A1 (es)	2006-06-29	2008-09-10	Merz Pharma Gmbh & Co Kgaa	Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en)	2006-06-29	2020-10-06	Merz Pharma Gmbh & Co. Kgaa	High frequency application of botulinum toxin therapy
FR2907680B1 (fr)	2006-10-27	2012-12-28	Scras	Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr)	2006-12-22	2013-04-26	Scras	Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
US8002717B2 (en)	2007-03-30	2011-08-23	Anders Fagergren	Quantification of mechanical and neural contributions to spasticity
EP3741380A1 (de)	2007-07-26	2020-11-25	ReVance Therapeutics, Inc.	Antimikrobielles peptid und zusammensetzungen davon
EP2072039A1 (de) *	2007-12-21	2009-06-24	Merz Pharma GmbH & Co.KGaA	Verwendung eines neurotoxischen Bestandteils des Clostridium-botulinum-Toxinkomplexes zur Verringerung oder Verhütung von Nebenwirkungen
US8470337B2 (en)	2008-03-13	2013-06-25	Allergan, Inc.	Therapeutic treatments using botulinum neurotoxin
FR2930447B1 (fr)	2008-04-25	2010-07-30	Sod Conseils Rech Applic	Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US20100124559A1 (en) *	2008-11-20	2010-05-20	Allergan, Inc.	Early Treatment and Prevention of Increased Muscle Tonicity
ES2908616T3 (es)	2008-12-31	2022-05-03	Revance Therapeutics Inc	Formulaciones inyectables de toxina botulínica
AU2010265888A1 (en)	2009-06-25	2012-01-19	Revance Therapeutics, Inc.	Albumin-free botulinum toxin formulations
US8147848B2 (en)	2009-08-26	2012-04-03	Allergan, Inc.	Method for treating premature ejaculation with a botulinum neurotoxin
MX370929B (es)	2012-10-28	2020-01-08	Revance Therapeutics Inc	Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
RU2545453C2 (ru) *	2013-03-21	2015-03-27	Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ лечения переломов нижней челюсти
US10149893B2 (en)	2013-09-24	2018-12-11	Allergan, Inc.	Methods for modifying progression of osteoarthritis
KR101677710B1 (ko) *	2014-06-30	2016-11-21	(주)메디톡스	보툴리눔 독소를 유효성분으로 포함하는 골관절염 치료용 약제학적 조성물 및 그를 이용한 골관절염 치료 방법
US11484580B2 (en)	2014-07-18	2022-11-01	Revance Therapeutics, Inc.	Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10369190B2 (en) *	2016-09-13	2019-08-06	Allergan, Inc.	Non-protein clostridial toxin compositions
US11191819B2 (en) *	2018-08-28	2021-12-07	Ira Sanders	Skin therapeutics
RU2732204C1 (ru) *	2020-01-28	2020-09-14	Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз"	Способ лечения головных болей напряжения по Гурову-Левину
US20230365957A1 (en) *	2020-10-07	2023-11-16	Pro-Tox Inc.	Vacuum drying method for botulinum toxin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4362731A (en) *	1980-09-01	1982-12-07	Sandoz Ltd.	Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4664911A (en)	1983-06-21	1987-05-12	Board Of Regents, University Of Texas System	Immunotoxin conjugates employing toxin B chain moieties
US5053005A (en)	1989-04-21	1991-10-01	Gary E. Borodic	Chemomodulation of curvature of the juvenile spine
GB9022250D0 (en) *	1990-10-12	1990-11-28	Glaxo Group Ltd	Medicaments
GB9120306D0 (en) *	1991-09-24	1991-11-06	Graham Herbert K	Method and compositions for the treatment of cerebral palsy
AU4646393A (en) *	1992-06-23	1994-01-24	Interactive Biologics Associates	Pharmaceutical composition containing botulinum b complex
EP0679090A1 (de) *	1993-01-15	1995-11-02	Interactive Biologics Associates	Verfahren zur behandlung von gesichtsmuskel schmez syndrom
DE122009000066I2 (de) *	1993-06-10	2010-12-30	Allergan Inc	Behandlung von neuromuskulären Störungen und Zuständen mit verschiedenen botulinen Serotypen
ES2194025T3 (es) *	1993-06-10	2003-11-16	Allergan Inc	Toxinas botulinicas multiples para tratar trastornos y enfermedades neuromusculares.
US5437291A (en) *	1993-08-26	1995-08-01	Univ Johns Hopkins	Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
ES2163090T3 (es) *	1993-12-28	2002-01-16	Allergan Sales Inc	Uso de toxina botulinica para tratar la cefalea tensional.
US5766605A (en) *	1994-04-15	1998-06-16	Mount Sinai School Of Medicine Of The City University Of New York	Treatment of autonomic nerve dysfunction with botulinum toxin
ATE292977T1 (de) *	1994-05-09	2005-04-15	William J Binder	Präsynaptische neurotoxine gegen migränekopfschmerzen
JP2001104991A (ja) *	1999-10-12	2001-04-17	Toyoaki Kubota	循環水の有機質除去剤

1994
- 1994-12-16 ES ES97200028T patent/ES2163090T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69428813T patent/DE69428813T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES00203421T patent/ES2223393T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES07002714T patent/ES2309973T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP05006665.3A patent/EP1563843B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP05016177A patent/EP1591129B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES99203735T patent/ES2237033T5/es not_active Expired - Lifetime
- 1994-12-16 EP EP97200028A patent/EP0770395B1/de not_active Expired - Lifetime
- 1994-12-16 CA CA002682117A patent/CA2682117A1/en not_active Abandoned
- 1994-12-16 ES ES05018368T patent/ES2334357T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES95906674T patent/ES2159624T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES08017803T patent/ES2347384T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP08017803A patent/EP2027872B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP01118793A patent/EP1147776B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435194T patent/DE69435194D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES00203294T patent/ES2246800T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP04019048A patent/EP1488803B1/de not_active Revoked
- 1994-12-16 DE DE69434319T patent/DE69434319T3/de not_active Expired - Lifetime
- 1994-12-16 EP EP95906674A patent/EP0737074B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69427869T patent/DE69427869T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP00203294A patent/EP1072270B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434535T patent/DE69434535T2/de not_active Revoked
- 1994-12-16 ES ES03015589T patent/ES2242126T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP07002714A patent/EP1790352B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP04000166A patent/EP1421948B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435116T patent/DE69435116D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE122009000038C patent/DE122009000038I1/de active Pending
- 1994-12-16 DE DE69435302T patent/DE69435302D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES05018367T patent/ES2339865T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES01118793T patent/ES2355491T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP03015589A patent/EP1366770B1/de not_active Revoked
- 1994-12-16 DE DE69435270T patent/DE69435270D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434511T patent/DE69434511T2/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434610T patent/DE69434610T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES04019047T patent/ES2247575T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP99203920A patent/EP1005867B2/de not_active Expired - Lifetime
- 1994-12-16 EP EP06016208A patent/EP1757325B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE122008000042C patent/DE122008000042I1/de active Pending
- 1994-12-16 DE DE69435243T patent/DE69435243D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434540T patent/DE69434540T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES99203920T patent/ES2207910T5/es not_active Expired - Lifetime
- 1994-12-16 JP JP51812795A patent/JP3238154B2/ja not_active Expired - Lifetime
- 1994-12-16 DE DE122008000043C patent/DE122008000043I1/de active Pending
- 1994-12-16 DE DE69435330T patent/DE69435330D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP99203735A patent/EP1010431B2/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434443T patent/DE69434443T2/de not_active Revoked
- 1994-12-16 ES ES05016177T patent/ES2340172T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP04019047A patent/EP1477183B1/de not_active Revoked
- 1994-12-16 EP EP05017284A patent/EP1602379A1/de not_active Withdrawn
- 1994-12-16 ES ES04019048T patent/ES2248780T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69435249T patent/DE69435249D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435321T patent/DE69435321D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP04019046A patent/EP1502600B1/de not_active Expired - Lifetime
- 1994-12-16 EP EP05018368A patent/EP1598077B1/de not_active Expired - Lifetime
- 1994-12-16 ES ES03015590T patent/ES2251651T3/es not_active Expired - Lifetime
- 1994-12-16 CA CA002180011A patent/CA2180011C/en not_active Expired - Lifetime
- 1994-12-16 EP EP00203421A patent/EP1103267B1/de not_active Revoked
- 1994-12-16 ES ES01118792T patent/ES2319860T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69433394T patent/DE69433394T3/de not_active Expired - Lifetime
- 1994-12-16 ES ES04019046T patent/ES2332905T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP04018914A patent/EP1486214A1/de not_active Withdrawn
- 1994-12-16 DE DE69434008T patent/DE69434008T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP05018367A patent/EP1600163B1/de not_active Expired - Lifetime
- 1994-12-16 WO PCT/US1994/014717 patent/WO1995017904A2/en active IP Right Grant
- 1994-12-16 DE DE69435149T patent/DE69435149D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP03015590A patent/EP1366771B1/de not_active Revoked
- 1994-12-16 AU AU15162/95A patent/AU688452B2/en not_active Ceased
- 1994-12-16 EP EP01118792A patent/EP1147775B1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435276T patent/DE69435276D1/de not_active Expired - Lifetime
2001
- 2001-06-11 HK HK01103981A patent/HK1033274A1/xx not_active IP Right Cessation
- 2001-07-16 JP JP2001214884A patent/JP2002087984A/ja active Pending
- 2001-07-16 JP JP2001214891A patent/JP2002097156A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214888A patent/JP2002068989A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214886A patent/JP2002087985A/ja active Pending
- 2001-07-16 JP JP2001214885A patent/JP2002097145A/ja active Pending
- 2001-07-16 JP JP2001214883A patent/JP2002114706A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214882A patent/JP2002104991A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214887A patent/JP2002087986A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214881A patent/JP2002104990A/ja active Pending
- 2001-07-16 JP JP2001214889A patent/JP2002087987A/ja active Pending
- 2001-07-16 JP JP2001214890A patent/JP2002087988A/ja active Pending
2004
- 2004-09-28 HK HK04107484.4A patent/HK1064599A1/xx not_active IP Right Cessation
2005
- 2005-04-28 HK HK05103646A patent/HK1070831A1/xx not_active IP Right Cessation
- 2005-05-10 HK HK05103928A patent/HK1071071A1/xx not_active IP Right Cessation
- 2005-06-20 HK HK05105116.3A patent/HK1072375A1/xx not_active IP Right Cessation
2006
- 2006-01-26 JP JP2006017860A patent/JP2006160756A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017857A patent/JP2006160753A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017858A patent/JP2006160754A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017859A patent/JP2006160755A/ja not_active Withdrawn
2007
- 2007-06-13 JP JP2007156168A patent/JP2007262086A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248739A patent/JP2008037877A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248742A patent/JP2008056683A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248745A patent/JP2008031176A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248736A patent/JP2008056682A/ja not_active Withdrawn
- 2007-10-26 JP JP2007278365A patent/JP2008063339A/ja not_active Withdrawn
- 2007-11-14 HK HK07112425A patent/HK1106700A1/xx not_active IP Right Cessation
2008
- 2008-08-27 FR FR08C0034C patent/FR08C0034I1/fr active Active
2010
- 2010-05-19 JP JP2010115454A patent/JP2010209105A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115462A patent/JP2010202659A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115469A patent/JP2010202660A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115472A patent/JP2010202661A/ja not_active Withdrawn
2012
- 2012-05-10 JP JP2012108652A patent/JP2012167115A/ja active Pending
- 2012-05-10 JP JP2012108649A patent/JP2012167114A/ja active Pending
- 2012-05-10 JP JP2012108658A patent/JP2012167116A/ja active Pending
- 2012-05-10 JP JP2012108662A patent/JP2012167117A/ja active Pending
- 2012-05-10 JP JP2012108656A patent/JP2012188433A/ja active Pending
- 2012-05-23 JP JP2012117085A patent/JP2012197287A/ja active Pending
- 2012-09-10 JP JP2012198070A patent/JP2013006865A/ja active Pending

Also Published As

Publication number	Publication date
DE69435243D1 (de)	2009-11-19
DE69428813D1 (de)	2001-11-29
DE122008000042I1 (de)	2009-01-02
EP1477183B1 (de)	2005-11-02
JP2010202659A (ja)	2010-09-16
ES2242126T3 (es)	2005-11-01
ES2246800T3 (es)	2006-03-01
DE69435249D1 (de)	2009-12-17
DE69427869D1 (de)	2001-09-06
DE69434319T2 (de)	2006-03-09
HK1072375A1 (en)	2005-08-26
EP1366770A3 (de)	2004-03-17
ES2159624T3 (es)	2001-10-16
ES2340172T3 (es)	2010-05-31
DE69434535D1 (de)	2005-12-08
HK1033274A1 (en)	2001-08-24
FR08C0034I1 (fr)	2008-09-26
JP2006160754A (ja)	2006-06-22
DE69434540D1 (de)	2009-03-26
JP2002114706A (ja)	2002-04-16
EP1072270A2 (de)	2001-01-31
ES2332905T3 (es)	2010-02-15
ES2309973T3 (es)	2008-12-16
ES2334357T3 (es)	2010-03-09
DE122009000038I1 (de)	2009-11-05
DE69435270D1 (de)	2010-04-01
ES2319860T3 (es)	2009-05-14
DE69434540T2 (de)	2009-06-18
EP1600163A1 (de)	2005-11-30
DE69427869T2 (de)	2002-04-11
DE69434511D1 (de)	2006-03-02
JP2012167117A (ja)	2012-09-06
JP2002104991A (ja)	2002-04-10
JP2002097145A (ja)	2002-04-02
DE69434319D1 (de)	2005-05-04
EP1502600B1 (de)	2009-10-07
EP1563843B1 (de)	2013-08-07
HK1106700A1 (en)	2008-03-20
EP1010431A3 (de)	2001-05-16
ES2237033T3 (es)	2005-07-16
DE69434535T2 (de)	2006-07-20
JP2010209105A (ja)	2010-09-24
EP0737074A1 (de)	1996-10-16
ES2355491T3 (es)	2011-03-28
JP2006160753A (ja)	2006-06-22
EP1147775A2 (de)	2001-10-24
JP2007262086A (ja)	2007-10-11
DE69435302D1 (de)	2010-08-26
EP1005867B1 (de)	2003-12-03
EP1366771B1 (de)	2008-03-26
JP2002087985A (ja)	2002-03-27
EP1103267A1 (de)	2001-05-30
EP1010431A2 (de)	2000-06-21
JP3238154B2 (ja)	2001-12-10
AU1516295A (en)	1995-07-17
EP1591129B1 (de)	2010-02-24
EP1147775A3 (de)	2003-01-15
AU688452B2 (en)	1998-03-12
WO1995017904A2 (en)	1995-07-06
EP1598077B1 (de)	2009-11-04
EP1598077A1 (de)	2005-11-23
EP1421948A3 (de)	2004-06-16
EP0770395B1 (de)	2001-10-24
JP2008031176A (ja)	2008-02-14
DE69434319T3 (de)	2011-02-17
JP2012167114A (ja)	2012-09-06
EP1147775B1 (de)	2009-03-04
EP1591129A2 (de)	2005-11-02
EP1600163B1 (de)	2010-02-17
DE69435149D1 (de)	2008-11-20
EP1005867A2 (de)	2000-06-07
ES2237033T5 (es)	2010-10-29
JP2010202661A (ja)	2010-09-16
JP2002104990A (ja)	2002-04-10
CA2180011C (en)	2001-05-15
JP2012167115A (ja)	2012-09-06
JP2012197287A (ja)	2012-10-18
JP2008056683A (ja)	2008-03-13
DE69433394T2 (de)	2004-10-14
ES2207910T3 (es)	2004-06-01
EP1488803A1 (de)	2004-12-22
JP2006160756A (ja)	2006-06-22
EP1602379A1 (de)	2005-12-07
JP2002087987A (ja)	2002-03-27
EP1010431B2 (de)	2010-07-14
WO1995017904A3 (en)	1995-10-19
EP2027872A1 (de)	2009-02-25
EP1421948A2 (de)	2004-05-26
EP1790352A1 (de)	2007-05-30
EP1790352B1 (de)	2008-07-09
DE69434008T2 (de)	2005-09-22
JP2002087988A (ja)	2002-03-27
JP2002087986A (ja)	2002-03-27
EP1591129A3 (de)	2005-11-16
EP1421948B1 (de)	2008-10-08
DE69428813T2 (de)	2002-04-04
EP1486214A1 (de)	2004-12-15
DE69434443D1 (de)	2005-09-01
EP1366771A2 (de)	2003-12-03
EP1563843A1 (de)	2005-08-17
EP1757325A1 (de)	2007-02-28
EP1103267B1 (de)	2004-09-15
EP1010431B1 (de)	2005-03-30
EP1488803B1 (de)	2008-03-26
EP1366770B1 (de)	2005-07-27
EP2027872B1 (de)	2010-07-14
ES2223393T3 (es)	2005-03-01
EP0737074B1 (de)	2001-08-01
EP0770395A1 (de)	1997-05-02
JP2010202660A (ja)	2010-09-16
JP2012188433A (ja)	2012-10-04
DE69435321D1 (de)	2010-12-16
JP2002097156A (ja)	2002-04-02
ES2248780T3 (es)	2008-06-16
DE69433394D1 (de)	2004-01-15
DE69434443T2 (de)	2006-05-24
ES2347384T3 (es)	2010-10-28
EP1005867A3 (de)	2001-06-13
EP1072270B1 (de)	2005-10-19
JP2002087984A (ja)	2002-03-27
JP2006160755A (ja)	2006-06-22
JP2008056682A (ja)	2008-03-13
DE69434008D1 (de)	2004-10-21
ES2247575T3 (es)	2006-03-01
JPH09507234A (ja)	1997-07-22
CA2180011A1 (en)	1995-07-06
EP1502600A1 (de)	2005-02-02
EP1477183A1 (de)	2004-11-17
JP2012167116A (ja)	2012-09-06
EP1072270A3 (de)	2002-08-07
JP2008063339A (ja)	2008-03-21
EP1757325B1 (de)	2010-11-03
DE69435116D1 (de)	2008-08-21
EP1005867B2 (de)	2010-02-17
ES2251651T3 (es)	2008-07-16
HK1070831A1 (en)	2005-06-30
EP1147776A3 (de)	2003-01-15
JP2013006865A (ja)	2013-01-10
HK1064599A1 (en)	2005-02-04
DE69434610D1 (de)	2008-08-21
CA2682117A1 (en)	1995-07-06
DE69435276D1 (de)	2010-04-08
ES2207910T5 (es)	2010-05-21
DE122008000043I1 (de)	2008-11-20
ES2339865T3 (es)	2010-05-26
EP1366770A2 (de)	2003-12-03
DE69433394T3 (de)	2010-08-12
EP1147776B1 (de)	2010-12-15
EP1147776A2 (de)	2001-10-24
EP1366771A3 (de)	2003-12-10
DE69434511T2 (de)	2006-07-13
DE69435194D1 (de)	2009-04-16
HK1071071A1 (en)	2005-07-08
JP2002068989A (ja)	2002-03-08
ES2163090T3 (es)	2002-01-16
JP2008037877A (ja)	2008-02-21
DE69434610T2 (de)	2008-11-27

Publication	Publication Date	Title
DE69435330D1 (de)	2011-01-27	Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen
DE69736183D1 (de)	2006-08-03	Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE122005000002I1 (de)	2005-05-12	Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE122009000012I1 (de)	2011-12-01	Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE59408901D1 (de)	1999-12-16	Verfahren zur Herstellung von Polyacetalen
DE59501599D1 (de)	1998-04-16	Verfahren zur Herstellung von Propandiol-1,2
DE59404719D1 (de)	1998-01-15	Verfahren zur Herstellung von Diarylcarbonaten
DE69317044D1 (de)	1998-03-26	Mittel zur regulierung vom hautfettigkeitsgrad
DE69407419D1 (de)	1998-01-29	2' oder 3' -deoxy- und 2' -dideoxy-beta-l-pentafuranonukleoside, verfahren zur herstellung und anwendung in der therapie, insbesondere als antivirale wirkstoffe
DE59400779D1 (de)	1996-11-14	Verfahren zur Herstellung von Hexafluorbuten
DE59101863D1 (de)	1994-07-14	Verfahren zur Herstellung von aromatischen Kohlensäurediestern.
DE69431373D1 (de)	2002-10-17	Verfahren zur Herstellung von optisch aktiven 2-Amino-1-Phenylethanol-Derivaten
DE69405919D1 (de)	1997-11-06	Zusammensetzungen zur Behandlung von Keratinfasern
ATE246518T1 (de)	2003-08-15	Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE69233725D1 (de)	2008-03-27	Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
DE69423577D1 (de)	2000-04-27	Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69434777D1 (de)	2006-08-10	Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE59408701D1 (de)	1999-10-07	Verfahren zur Herstellung von 2,3,4,5-Tetrafluor-benzotrifluorid
DE69103473D1 (de)	1994-09-22	Verfahren zur Herstellung von 1-Chlor-1,2,2-trifluorethylen oder von 1,2,2-trifluorethylen.
DE69232911D1 (de)	2003-03-06	Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
DE59501060D1 (de)	1998-01-15	Verfahren zur Herstellung von 2,5-Dihydrofuran
DE69313297D1 (de)	1997-09-25	Benzofuranone, benzodifurantrione und verfahren zur herstellung von benzodifurandionen
DE69300037D1 (de)	1995-02-09	Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
FI944687L (fi)	1995-04-08	Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi
DE69616913D1 (de)	2001-12-20	Verfahren zur Herstellung von 3,7-Dimethyl-5,7-octadien-1-ol oder Rosenoxid